Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
standard first-line treatment for most patients with hormone receptor (HR) positive, human …
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence
Simple Summary Risk assessment in early breast cancer is critical for clinical decisions, but
defining risk categories poses a significant challenge. The integration of conventional …
defining risk categories poses a significant challenge. The integration of conventional …
HER2-low breast cancer: current landscape and future prospects
Y Shirman, S Lubovsky, A Shai - Breast Cancer: Targets and …, 2023 - Taylor & Francis
More than 50% of breast cancers are currently defined as “Human epidermal growth factor
receptor 2 (HER2) low breast cancer (BC)”, with HER2 immunohistochemistry (IHC) scores …
receptor 2 (HER2) low breast cancer (BC)”, with HER2 immunohistochemistry (IHC) scores …
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
S Ahuja, AA Khan, S Zaheer - Pathology-Research and Practice, 2024 - Elsevier
HER2 (human epidermal growth factor receptor 2) status in breast cancer spans a spectrum
from HER2-positive to ultra-low HER2, each category influencing prognosis and treatment …
from HER2-positive to ultra-low HER2, each category influencing prognosis and treatment …
[HTML][HTML] Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
S Terán, M Alva, P Tolosa, M Rey-Cárdenas… - The Breast, 2023 - Elsevier
Background HER2-low has emerged as a new predictive biomarker in metastatic breast
cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We …
cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We …
[HTML][HTML] Think “HER2” different: Integrative diagnostic approaches for HER2-low breast cancer
This work explores the complex field of HER2 testing in the HER2-low breast cancer era,
with a focus on methodological aspects. We aim to propose clear positions to scientific …
with a focus on methodological aspects. We aim to propose clear positions to scientific …
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis
Background Breast cancer during pregnancy (PrBC) is a rare condition known for its
aggressive clinical behavior. The presence of tumor-infiltrating lymphocytes (TILs) has been …
aggressive clinical behavior. The presence of tumor-infiltrating lymphocytes (TILs) has been …
[HTML][HTML] Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges
For the past 2 decades, pathologists have been accustomed to reporting the HER2 status of
breast cancer as either positive or negative, based on HER2 IHC. Today, however, there is a …
breast cancer as either positive or negative, based on HER2 IHC. Today, however, there is a …
[HTML][HTML] Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
Introduction Estrogen receptor (ER) loss at metastatic relapse occurs in up to 20% of luminal-
like primary breast tumors. Data about clinicopathological features associated with ER loss …
like primary breast tumors. Data about clinicopathological features associated with ER loss …